Zepbound Beats Wegovy in First Head-to-Head Trial
Eli Lilly’s GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk’s Wegovy, according to the trial results.
Condie Carmack
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and Metabolism and presented at the annual meeting of…
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.
GLP-1 receptor agonists show anti-cancer benefits beyond weight loss
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the journal eClinicalMedicine finds that first-generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.
Trump veers into erratic tale of ‘seriously overweight’ friend’s ‘damn fat drug’ struggle
In an erratic soliloquy before he signed an executive order to bring down the price of prescription drugs, President Donald Trump took aim at the “fat shot drug” he said was an example of how Big Pharma inflates the cost of medications. Trump was presumably talking about the popular GLP-1 drugs on the market under … Read more
Zepbound tops Wegovy for weight loss in study comparing the drugs
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation
CHICAGO–(BUSINESS WIRE)– #CardiometabolicResearch–Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the … Read more
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation – Business Wire
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation Business Wire
Zepbound helps users lose more weight than Wegovy, new trial reveals
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation – BioSpace
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation BioSpace